AFP and gastric cancer: The findings suggested that apatinib combined with paclitaxel-based chemotherapy might be effective and tolerable in patients with chemotherapy-refractory GC (10); apatinib combined with S-1 was not superior to other chemotherapy regimens as first-line therapy for advanced GC (12); apatinib plus neoadjuvant chemotherapy followed by resection in patients with locally advanced gastric adenocarcinoma showed favorable activity and manageable safety (11); apatinib showed promising efficacy and an acceptable safety profile in patients with advanced alpha-fetoprotein-producing GC (13).